Reduced sTWEAK and increased sCD163 levels in HIV-infected patients: modulation by antiretroviral treatment, HIV replication and HCV co-infection. - Wikidata - awgldk - TriplyDB

Reduced sTWEAK and increased sCD163 levels in HIV-infected patients: modulation by antiretroviral treatment, HIV replication and HCV co-infection.

Reduced sTWEAK and increased sCD163 levels in HIV-infected patients: modulation by antiretroviral treatment, HIV replication and HCV co-infection.

http://www.wikidata.org/entity/Q31152445

about

Influence of immune activation and inflammatory response on cardiovascular risk associated with the human immunodeficiency virus Pre-clinical carotid atherosclerosis and sCD163 among virally suppressed HIV patients in Botswana compared with uninfected controls.Latent and Active Tuberculosis Infection Increase Immune Activation in Individuals Co-Infected with HIV Late Antiretroviral Therapy (ART) Initiation Is Associated with Long-Term Persistence of Systemic Inflammation and Metabolic Abnormalities.HIV-1/HAART-Related Lipodystrophy Syndrome (HALS) Is Associated with Decreased Circulating sTWEAK Levels.Circulating Soluble CD163 is Associated with Steatohepatitis and Advanced Fibrosis in Nonalcoholic Fatty Liver Disease Biomarkers of inflammation in HIV-infected Peruvian men and women before and during suppressive antiretroviral therapy.Inflammation, immune activation, and cardiovascular disease in HIV.Pathophysiology and management of cardiovascular disease in patients with HIV Risk of coronary heart disease in patients with HIV infection.Immune activation in the course of HIV-1 infection: Causes, phenotypes and persistence under therapy.Soluble TWEAK may predict carotid atherosclerosis in treated HIV infection.The role of tumor necrosis factor-like weak inducer of apoptosis in atherosclerosis via its two different receptors.Telmisartan increases vascular reparative capacity in older HIV-infected adults: a pilot study.HIV infection, antiretroviral therapy, and measures of endothelial function, inflammation, metabolism, and oxidative stress.Plasma Soluble CD163 Level Independently Predicts All-Cause Mortality in HIV-1-Infected Individuals.Systemic inflammation and liver damage in HIV/hepatitis C virus coinfection.Transcriptomics and Targeted Proteomics Analysis to Gain Insights Into the Immune-control Mechanisms of HIV-1 Infected Elite Controllers.Noncommunicable diseases in adolescents with perinatally acquired HIV-1 infection in high-income and low-income settings.

P2860

Q26851535-BD789CD3-06BD-4542-9191-098B787FE2F8 Q33853259-A3375D4F-599C-4A3D-A4B0-FBF35590F7A7 Q35766808-10651B70-7552-4223-BD8B-5A987B987315 Q35860942-8C94513D-D040-477C-875F-E045469D2BD1 Q35866999-F00B5AB9-CA56-4433-B3F9-EB2612460895 Q36751382-84B1A7AA-2196-47F0-A9C3-2EED1FDD6FF7 Q36775142-7E155AAD-CE5E-4094-8CDE-BA46B2EA44F9 Q36957752-90BFB076-76A2-4331-82AD-283BA29CF105 Q37038775-5AD1C702-6F92-465D-B39F-DC4DA14FA952 Q38261508-F0BD5FE3-C0CB-4EA6-9EED-5CAF10EBF7DA Q38603237-6DC522AC-FA73-4945-88A6-6E0D514B46D5 Q38614592-923AA4EF-30FB-4496-B8B9-436A2BAB89E8 Q38638020-630CC0EE-310B-4EA9-80F5-A73803AAADB2 Q39361501-B6460FA6-9B45-4DA8-9349-9873B4AF74A3 Q40089833-6B63BDEC-128A-4468-8EF1-E74A72C9410D Q40632660-0C3AF828-E4A5-47AE-A91D-61242CC98023 Q40671632-80AD87DD-680C-4D14-AAAF-1BC368BF8F0D Q47263592-7D598111-B406-45D5-8CEC-45BB55A8F7FA Q50063465-4A1B599A-99A1-48B6-8386-27D82E7983BE

P2860

Reduced sTWEAK and increased sCD163 levels in HIV-infected patients: modulation by antiretroviral treatment, HIV replication and HCV co-infection.

http://www.wikidata.org/entity/Q31152445

description

2014 nî lūn-bûn

@nan

2014 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի մարտին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Reduced sTWEAK and increased s ...... lication and HCV co-infection.

@ast

Reduced sTWEAK and increased s ...... lication and HCV co-infection.

@en

type

label

Reduced sTWEAK and increased s ...... lication and HCV co-infection.

@ast

Reduced sTWEAK and increased s ...... lication and HCV co-infection.

@en

prefLabel

Reduced sTWEAK and increased s ...... lication and HCV co-infection.

@ast

Reduced sTWEAK and increased s ...... lication and HCV co-infection.

@en

P1433

Q31152445-9C664C7B-CA93-4F24-8B5E-14001726B5EF

P1476

Q31152445-1941BAFF-0EB6-43A5-A035-3BD8D445A49D

P2093

Q31152445-17614ADE-971F-48B2-B5EB-ED6FCB68F7A5

Q31152445-321B2E20-35F7-4A85-A041-E0C9F13806DD

Q31152445-57BBBC5B-5CC2-4822-A916-E47563BEC7A0

Q31152445-9C45CB1C-A5C5-4E54-B965-0BF11BC29CB1

Q31152445-A53C402A-3B13-40E0-9F66-A775DEA9D6CD

Q31152445-C65D8103-D115-4EC7-B9F2-D639844B1B0F

Q31152445-C7888AE9-F8F9-48FC-A2FF-427CACC90075

Q31152445-EE4398A3-A8E0-421F-BEA1-83075D1B2F69

P2860

Q31152445-04E0757B-30BB-4D64-ADE7-6636823A078D

Q31152445-0BDE94D0-1882-4772-A267-B3A007CD7744

Q31152445-0CA35DBA-B52D-4AFD-AB1E-2F4D33C6C2B5

Q31152445-138014FD-3A63-45EF-9653-83D16127AF57

Q31152445-142A0FA2-7CF1-4160-AF7F-3CA021210CB3

Q31152445-15A1042C-352E-429F-832F-E62FA5C4FEBB

Q31152445-166F1505-6AA1-4506-A692-3849D1A654EA

Q31152445-1F235DBB-82E3-415A-BFCE-B35878385320

Q31152445-22572701-DB8D-4352-86F2-7453BD2252A5

Q31152445-2F6B572F-A929-4A1C-AD8F-FC072AE127DC

P304

Q31152445-326E10F6-F6CE-4C09-8234-987B2B0394F3

P31

Q31152445-9648DA41-03E3-448C-A1C2-D1F2670A3577

P356

Q31152445-83847AA3-92BE-4BF7-B80C-2EC34197D485

P407

Q31152445-599E2100-CC70-4360-ACCA-BEDFA74CD8AB

P433

Q31152445-C31A7A17-29A0-4FCA-B8EC-723CA9FE9EBB

P478

Q31152445-9509AE96-60A1-4EC2-A481-8AF9001EFCD5

P50

Q31152445-3EBC0A93-F458-4A9A-91F6-A8DB1AA7AA99

Q31152445-7994D021-4373-4CE7-81FD-68B54838AB7E

Q31152445-800D7FCD-0459-4F95-BEFA-BBB350F9DA55

Q31152445-C9852A3A-C660-4666-875E-5880AA2A2DEE

P577

Q31152445-C406399D-26F8-4170-AC95-471C9AD7347A

P5875

Q31152445-55115307-B043-4B03-92E3-6872B914239E

P698

Q31152445-B4682332-040F-4608-93E7-69FC864AA48C

P921

Q31152445-1834473D-227E-49D3-A185-1BCE67C05EAF

Q31152445-9B80391B-1C31-409A-BBA8-0DE00A408963

P932

Q31152445-B14F0365-1174-470C-967C-E237576FF4C0

P356

JOURNAL.PONE.0090541

P1433

P1476

Reduced sTWEAK and increased s ...... lication and HCV co-infection.

@en

P2093

Jesús Egido

http://www.w3.org/2001/XMLSchema#string

José R Villar

http://www.w3.org/2001/XMLSchema#string

José S García Morillo

http://www.w3.org/2001/XMLSchema#string

Manuel Leal Noval

http://www.w3.org/2001/XMLSchema#string

Miguel Genebat

http://www.w3.org/2001/XMLSchema#string

Rebeca S de Pablo Bernal

http://www.w3.org/2001/XMLSchema#string

Rocío Muñoz Hernández

http://www.w3.org/2001/XMLSchema#string

Sara Ferrando-Martinez

http://www.w3.org/2001/XMLSchema#string

P2860

Fn14 is upregulated in cytokine-stimulated vascular smooth muscle cells and is expressed in human carotid atherosclerotic plaques: modulation by atorvastatin

TWEAK can induce pro-inflammatory cytokines and matrix metalloproteinase-9 in macrophages

TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis

Inflammatory and coagulation biomarkers and mortality in patients with HIV infection

Characterization of murine TWEAK and its receptor (Fn14) by monoclonal antibodies

CD4+ count-guided interruption of antiretroviral treatment

Dynamics of immune reconstitution and activation markers in HIV+ treatment-naïve patients treated with raltegravir, tenofovir disoproxil fumarate and emtricitabine

Identification of soluble tumor necrosis factor-like weak inducer of apoptosis (sTWEAK) as a possible biomarker of subclinical atherosclerosis.

A previously unrecognized protein-protein interaction between TWEAK and CD163: potential biological implications.

Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study.

P304

e90541

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0090541

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P50

Luis M Blanco-Colio

Rafael Moreno-Luna

Luis M Beltrán

P577

2014-03-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

260526834

http://www.w3.org/2001/XMLSchema#string

P698

24594990

http://www.w3.org/2001/XMLSchema#string

P921

antiretroviral drug

P932

3942443

http://www.w3.org/2001/XMLSchema#string